There are several programs that regulate it. Many terms and definitions are used to describe how a patient may get access to an unapproved drug outside of a clinical trial. Drug companies, patient advocacy groups, and the FDA all may use different terms for the same things. The FDA provides definitions for the terms they use in their regulations. But most drug companies use different terms that are unique to their specific compassionate access programs.